Compare drug alternatives
Incruse Ellipta ® Alternatives
Incruse Ellipta ®(Umeclidinium) | Trelegy Ellipta ®(Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate) |
|---|---|
Prescription Only | Prescription Only |
| Dosage & Administration | Dosage & Administration comparison data |
Administration | |
Dosing | |
Latin Shorthand | |
| Financial Assistance | Financial Assistance comparison data |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | |
Annual Cap | |
Assistance Expiration | |
12/31/2023. Learn more. | |
Generics | |
Lower-cost generic available | No lower-cost generic available |
| Physician Advisory | Physician Advisory comparison data |
Adverse Reactions | |
Most common adverse reactions (incidence ≥2% and more common than
placebo) include nasopharyngitis, upper respiratory tract infection, cough,
arthralgia.. Learn more. | COPD: Most common adverse reactions (incidence ≥1%) are upper
respiratory tract infection, pneumonia, bronchitis, oral candidiasis,
headache, back pain, arthralgia, influenza, sinusitis, pharyngitis, rhinitis,
dysgeusia, constipation, urinary tract infection, diarrhea, gastroenteritis,
oropharyngeal pain, cough, and dysphonia. (6.1)
Asthma: Most common adverse reactions (incidence ≥2%) are
pharyngitis/nasopharyngitis, upper respiratory tract infection/viral upper
respiratory tract infection, bronchitis, respiratory tract infection/viral
respiratory tract infection, sinusitis/acute sinusitis, urinary tract infection,
rhinitis, influenza, headache, and back pain.. Learn more. |
Mechanism of Actions (MoA) | |
Anticholinergics. Learn more. | Anticholinergics . Learn more. |
Special Populations | |
8.1 Pregnancy Risk Summary Insufficient data are available on the use of umeclidinium in pregnant women to determine a drug-associated risk. Animal studies with pregnant rats and rabbits, exposed to umeclidinium through inhalation or subcutaneous routes, showed no adverse effects on embryofetal development at exposures approximately 50 and 200 times, respectively, the human exposure at the maximum recommended daily inhaled dose (MRHDID). 8.2 Lactation Risk Summary There is no information regarding the presence of umeclidinium in human milk, its effects on breastfed infants, or its impact on milk production. Umeclidinium was detected in the plasma of offspring from lactating rats treated with umeclidinium, suggesting its presence in maternal milk. The decision to breastfeed should consider the benefits of breastfeeding along with the clinical need for INCRUSE ELLIPTA, weighing potential effects on the breastfed child from umeclidinium or the maternal condition. 8.4 Pediatric Use INCRUSE ELLIPTA is not approved for use in children, and its safety and efficacy in pediatric patients have not been established. 8.5 Geriatric Use Available data do not suggest the need for dosage adjustment of INCRUSE ELLIPTA in geriatric patients. However, some older individuals may exhibit greater sensitivity, although no overall differences in safety or effectiveness were observed in clinical trials between elderly and younger subjects. 8.6 Hepatic Impairment Patients with moderate hepatic impairment (Child-Pugh score of 7-9) did not show relevant increases in Cmax or AUC, and protein binding did not differ from healthy controls. Studies in subjects with severe hepatic impairment have not been conducted. 8.7 Renal Impairment Patients with severe renal impairment (CrCl <30 mL/min) did not exhibit relevant increases in Cmax or AUC, and protein binding did not differ from healthy controls. No dosage adjustment is required for patients with renal impairment. | 8.1 Pregnancy Risk Summary Insufficient data are available on the use of TRELEGY ELLIPTA or its individual components (fluticasone furoate, umeclidinium, and vilanterol) in pregnant women to determine a drug-associated risk. Animal studies showed no adverse effects on embryofetal development for these components at exposures approximately 4.5 to 200 times the maximum recommended daily inhalation doses in adults. 8.2 Lactation Risk Summary No information is available on the presence of these components in human milk, their effects on the breastfed child, or milk production. Umeclidinium was detected in the plasma of offspring of lactating rats treated with umeclidinium, suggesting its presence in maternal milk. 8.4 Pediatric Use TRELEGY ELLIPTA is not approved for use in pediatric patients, and its safety and efficacy in pediatric patients have not been established. 8.5 Geriatric Use No dosage adjustment is necessary for geriatric patients, but greater sensitivity in some older individuals cannot be ruled out. 8.6 Hepatic Impairment TRELEGY ELLIPTA has not been studied in subjects with hepatic impairment. Information on the individual components is provided. 8.7 Renal Impairment TRELEGY ELLIPTA has not been studied in subjects with renal impairment. Information on the individual components is provided. |